

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4/A  
5-28-02  
RP

In re Application: Glover et al.

Serial No.: To be Assigned

Examiner: E. Crane

Filing Date: To be Assigned

Art Unit: 1623

For: NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL  
BENZIMIDAZOLE COMPOUNDCommissioner for Patents  
Washington D.C. 20231PRELIMINARY AMENDMENT

Sir:

Prior to the first Office Action, please amend and reconsider the instant application in view of the following amendments and remarks.

In the Specification:

At page 1, line 1, please insert the following new paragraph:

~~Cross-References to Related Applications~~

This application is a continuation of U.S. Patent Application Serial No. 09/647,962, filed 6 October 2000, which is a Rule 371 Application of PCT/EP99/02214, filed 1 April 1999, which claims priority to Great Britain Patent Application No. 9807354.7, filed 7 April 1998.

In the Claims:

Please cancel claims 1-10, 12, 13 and 15. Please amend claims 11 and 14 as follows. Please add new claims 16-21. The following clean claims reflect the amendments being made herein. A marked-up copy of the amended claims is attached hereto.

11. (Amended) A pharmaceutical composition comprising a crystalline form of Form II 5,6-dichloro-2-(isopropylamino)-1- $\beta$ -L-ribofuranosyl-1H-benzimidazole having substantially the same X-ray powder diffraction pattern as Figure 2, wherein